- In May 2022, Abbott announced United States Food and Drug Administration (FDA) clearance for its Alinity m STI Assay. After delays in care delivery during the pandemic contributed to a decline in routine STI screening and an increase in cases, the first-of-its-kind multiplex test will help address rising STI rates. Abbott's Alinity m system, the company's most advanced high-volume laboratory molecular equipment, is used for the test. Alinity m detects infectious infections using polymerase chain reaction (PCR) technology, which has a high sensitivity. This test can assist healthcare providers in saving time, increasing efficiency, and providing better patient care
Frequently Asked Questions
The market is segmented based on Global Sexually Transmitted Infections (STIs) Market Segmentation, By Type (HIV/AIDS, Human Papilloma Virus (HPV), Gonorrhea, Syphilis, Others), Treatment (Antibiotics, Antiviral), Route of Administration (Oral, Parenteral, Others), Location of Testing (Laboratory Testing, Point-of-care (POC) Testing), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
.
The Global Sexually Transmitted Infections Stis Market size was valued at USD 69.63 USD Billion in 2024.
The Global Sexually Transmitted Infections Stis Market is projected to grow at a CAGR of 12.04% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
